RxDoctor Payments Data

James Vincens, MD

Cardiovascular Disease · Johnson City, NYNPI 1033162730

Payments from drug & device makers

$414in general payments, 2019–2025

Across 27 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$71
  • Novartis$69
  • Amgen$66
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$61
  • Astellas Pharma US Inc$50
  • Boehringer Ingelheim$30
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$414 in reported general payments places this provider in the 25th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$57,629
Medicare patients
788
Services billed
1,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$162,646
EntrestoSacubitril/Valsartan49$80,176
JardianceEmpagliflozin43$42,860
XareltoRivaroxaban17$25,627
FarxigaDapagliflozin Propanediol27$24,464
Metoprolol Succinate357$6,874
Atorvastatin Calcium381$5,165
Ezetimibe109$2,566
Ranolazine ErRanolazine13$1,699
Rosuvastatin Calcium88$1,469
Valsartan32$1,135
Spironolactone132$1,122
Isosorbide Mononitrate ErIsosorbide Mononitrate49$1,073
Digoxin27$948
Losartan Potassium54$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$69$80,17649 claims
Boehringer IngelheimJardiance$30$42,86043 claims
Johnson & JohnsonXarelto$71$25,62717 claims
AstraZenecaFarxiga$14$24,46427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →